The in vivo capacity of AKS-107 to specifically target insulin-reactive B cells was determined using VH125Tg/NOD mice because this strain has elevated insulin-reactive B cell frequencies measurable via flow cytometry that correlate with exacerbated spontaneous diabetes onset and frequency, but retaining the non-insulin-binding B cell repertoire (31). Here, INS is linked to diabetes mellitus.